While 2006 did not record as many upsetting revelations of adverse drug reactions as the previous few years, still some data have been produced, which modulate the safety profile of drugs and deserve the attention of the prescribers: cardiovascular events under erythropoietins, macular oedema under rosiglitazone, vascular and renal complications of aprotinine, drawbacks of long-term linezolide administration, intracranial haemorrhage under tipranavir, anyphylaxis with pegaptanib, cardiototoxicity of imatinib, lymphomas with infliximab, bone pain and aches under bisphosphonates, cardiovascular events related to methylphenidate, congenital anomalies ascribed to paroxetine and lamotrigine, neonatal pulmonary hypertension related to serotonine reuptake inhibitors, infantile respiratory depression under promethazine.